Indolent systemic mastocytosis (ISM) is one of the five subtypes of systemic mastocytosis, a condition characterized by the ...

Systemic mastocytosis (SM) is characterized by an abnormal accumulation of mast cells, a type of immune cell present throughout the body that contributes to allergic and inflammatory responses ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

Joan Smith spent almost 40 years believing she suffered from severe allergies. Medical professionals frequently dismissed her ...

Healthcare Analysts provide expert insights on current and emerging treatments for Systemic Mastocytosis (relevant companies Blueprint ...

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors with a PDGFRA exon 18 mutation as well advanced systemic mastocytosis and ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

Avapritnib has been approved to treat advanced systemic mastocytosis and indolent systemic mastocytosis and gastrointestinal stromal tumors with a platelet-derived growth factor receptor alpha (PDGFRA ...

“The expanded SUMMIT data presented at AAAAI 2025 reinforce our belief that bezuclastinib can rapidly and meaningfully improve a wide variety of symptoms that impact the daily lives of patients with ...